Non-invasive breath biomarkers for early detection and precision medicine

The Breath Biopsy platform provides biomarker discovery and validation capabilities to support development of applications in precision medicine for a wide range of other medical conditions. Highly sensitive and selective, our platform allows for early diagnosis when treatments are more effective and more lives can be saved.

Owlstone Medical is involved in studies related to major and rapidly growing health concerns including lung cancer, asthma and liver disease. We are also participants in extensive partnerships focusing on multiple cancer types, pulmonary hypertension, mesothelioma, workplace exposures and much more.

Our Breath Biopsy Products and Services are available to academic, clinical and pharma research partners who want to develop breath based diagnostics for their own applications.

Owlstone Medical Ltd. Videos

Owlstone FAIMS Chip - Video

Wisenave Arulvasan and Ace Hatch - The Breath Biopsy Conference 2022 - Video

Breath Biopsy Collection Station - Video

Introducing Owlstone Medical - Breath Biopsy for Non-invasive Biomarkers - Video